Scenarios and Signals
The seven chapters before this one built the pieces; this one fits them together. Whether Doximity's growth reset is a ceiling or a soft patch is genuinely two-sided, and no further analysis of the March-2026 numbers will settle it. What settles it is a short list of datable prints over the next year. At $21.77 the price already sits near the ceiling case [1]: with the stock at the ceiling column, the recovery and the AI-Search optionality carry essentially no value in the current quote.
The reconciliation
The report has assembled real evidence on both sides. The honest reading is not that one column is right and the other noise — it is that the same four-quarter window carries a datable external shock and a retention slide that reached the anchor accounts, and the two cannot yet be separated.
| The cyclical read (soft patch) | The structural read (ceiling) |
|---|---|
| A datable external cause: 16 of the top-20 pharma customers signed most-favored-nation pricing agreements with the White House in late December–early January, disrupting the annual upfront [2] | Net revenue retention fell every quarter of FY2026 — 118% → 118% → 112% → 109% — and reached the top-20 anchor cohort, from 119% to 114% [3] |
| Deals slipped rather than vanished: January pharma bookings grew at the fastest rate since the 2021 IPO [4] | Management guided FY2027 to roughly market-level growth — "more in line with the market, maybe slight outperformance" — after years of ~2× the market [5] |
| Engagement is at record levels and free cash flow rose 19% to $317M, 49% of revenue — the machine is intact [6] | Several top-20 clients moved from annual to 3–6 month commitments, cutting forward visibility [7] |
| A self-funded, near-free option: commercial AI Search launched in late April, with a ramp expected in the fiscal back half [8] | An AI-native competitor, OpenEvidence, is now named directly in the 10-K's competition disclosures [9] |
Sources: FY2026 earnings-call transcripts and the FY2026 10-K, as cited. The two reads are examined in depth in The Upfront Shock and The Moat.
The single fact that keeps both columns live is that the retention slide reached the biggest customers. A pure air-pocket in discretionary spend would spare the top-20; instead the top-20 net revenue retention fell to 114% and the over-$500,000 cohort's year-over-year growth roughly halved to 6%, with the count ticking down between the third and fourth quarters [10]. The cyclical case has an answer — the MFN shock hit exactly those anchor accounts — but the answer is a promise about money not yet collected, which the next year's prints resolve.
Three scenarios, and where the price sits
The valuation work in What the Price Implies capitalizes the same cash flow three ways. The scenarios below are not forecasts; they are the fair values that fall out of a 10% discount rate at three durable growth rates, shown on both cash bases — reported free cash flow (~$317M) and the stricter owner cash that nets out stock compensation (~$205M).
Scenario fair values from the chapter-5 DCF (10% WACC, five-year explicit plus Gordon terminal), on reported FCF ~$317M and SBC-adjusted owner cash ~$205M [11]. Not a forecast; a map from growth assumption to value.
Two things fall out of this table. First, the $21.77 price sits between the ceiling and steady cases on reported free cash flow, and at the steady case on the stricter owner-cash base — so the market is not pricing decline, but it is pricing something close to no durable growth, and it awards the AI-Search re-acceleration column essentially nothing [12]. Second, the spread that matters is not ceiling-versus-re-acceleration; it is which cash base you capitalize. The $122 million of stock compensation that lifts Doximity's free cash flow to $317 million above its $196 million of net income is also what decides its valuation: on reported free cash flow it trades at ~10x, but net that compensation out and owner cash is ~$205 million — ~16x, whose steady-growth DCF is ~$21, essentially today's $21.77 price. On reported FCF even the ceiling case is near today's price and the steady case is ~40% above it; on owner cash the steady case is today's price. The stock is cheap only if you both believe growth holds near 5% and accept the pre-stock-compensation cash number.
The signals that resolve it
Because the reconciliation cannot be closed from the March-2026 record, the useful output of this report is not a verdict but a watch-list — specific, datable prints, each of which pushes the read toward cyclical or structural. As of this writing the first fiscal-2027 quarter (ended June 2026) has not yet been reported, so every item below is live.
| Signal | What confirms cyclical | What confirms structural | When it prints |
|---|---|---|---|
| Double-digit exit — management's benchmark to exit the calendar year as a double-digit grower | Growth re-accelerating through the fiscal back half toward double digits | Growth stuck at or below the guided ~4% into calendar year-end | Q3 FY2027 (Feb 2027) |
| AI Search revenue — first commercial deals closed late April, ramp guided to the fiscal back half [13] | Disclosed, growing AI-Search revenue; the option starts to pay | Silence or de-emphasis; the option stays theoretical while the cost stays in the P&L | Q2–Q3 FY2027 |
| NRR stabilization — the four-quarter slide to 109%, top-20 to 114% [14] | Net revenue retention flattens or ticks up, especially in the top-20 | Continued decline through 109%, with the anchor cohort still eroding | Each quarter |
| Commitment horizon — top-20 clients moved to 3–6 month buys [15] | A return to annual commitments as policy noise fades | The shorter horizon persists — a durable change in how pharma buys | FY2027 calls |
| Buyback at the cheaper price — $493M remaining, now deploying below the DCF range [16] | Aggressive repurchase at ~$22 shrinks the count materially | Slow deployment, or spend that again leads the price | Each quarter |
| Peer confirmation — is the HCP digital-ad softness market-wide? | Medscape/WebMD and OPRX report the same upfront disruption | The weakness looks Doximity-specific — lost share, not a soft market | Peer prints |
Signal thresholds drawn from management's own FY2026 commentary and guidance, as cited. The management benchmark and booking mechanics are set out in The Upfront Shock.
The order of these signals matters. The double-digit exit and NRR stabilization arrive first and speak to the cycle; AI-Search disclosure arrives later and speaks to the structure. A reader watching only the second, more exciting question will get the answer to the first one — is the base business cyclical or capped — several quarters sooner, and that is the answer the price is most sensitive to today.
What this leaves the reader with
The decisive variable is narrow: whether the top-20 pharma budgets that slipped past the December upfront are spent later at a normal rate, or spent smaller — or not at all. If they return, the ceiling case is wrong and a stock priced near no-growth re-rates on a cash stream that never broke [17]. If the anchor-account retention keeps sliding through 109% while AI Search stays a slide, the market's re-rate to ~10× free cash flow will look early rather than wrong. The asymmetry is real but not free: the current price already discounts the ceiling case, while the same policy shock that could be dismissed as timing is the one thing that reached the customers a ceiling would claim. The report's contribution is to have made the ceiling-versus-cycle question falsifiable — and to have named the quarters in which it gets its answer.